<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166685">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02153398</url>
  </required_header>
  <id_info>
    <org_study_id>D961TC00002</org_study_id>
    <secondary_id>26-022</secondary_id>
    <nct_id>NCT02153398</nct_id>
  </id_info>
  <brief_title>A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases</brief_title>
  <official_title>An Open-label, Parallel-group, Multi-centre, Phase I/III Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Once-daily Oral Administration of D961H 10 mg and D961H 20 mg in Japanese Paediatric Patients 1 to 14 Years Old With Gastrointestinal Acid Related Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and
      efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in
      Japanese paediatric patients aged 1 to 14 years old who either have a diagnosis of or are
      suspected to have gastric ulcer (GU), duodenal ulcer (DU), anastomotic ulcer (AU),
      non-erosive reflux esophagitis disease (NERD), reflux esophagitis (RE) or Zollinger-Ellison
      syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety of D961H in terms of a panel of safety measures: adverse events, physical examination, vital signs and laboratory variables</measure>
    <time_frame>From baseline to 8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic variabilities by assessment of the percentages of time with intragastric pH &gt;4 and pH&gt;3 (percent of the time)</measure>
    <time_frame>Pre dose (Week 0) and after at least 5 days of repeated dose (Week 1,4 or 8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of esomeprazole and its metabolites by assessment of AUCtau, AUC0-t, Cmax, tmax, t½, CL/F and Vz/F</measure>
    <time_frame>Pre dose (Week 0) and after at least 5 days of repeated dose (Week 1,4 or 8)</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUCtau, AUC0-t, Cmax, tmax, and t1/2 (For all) CL/F, Vz/F (For esomeprazole only) AUCtau:Area under the curve during a dosing interval, AUC0-t:AUC from time zero to time of last quantifiable concentration, Cmax:Maximum plasma concentration,tmax: Time to reach maximum plasma concentration, t½: Elimination half-life, CL/F: Apparent total clearance and Vz/F: Apparent volume of distribution during terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of disappearance or aggravation of gastrointestinal symptom assessed by the investigators and the patient diaries</measure>
    <time_frame>From baseline to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic variabilities by assessment of median intragastric pH during 12 hours</measure>
    <time_frame>Pre dose (Week 0) and after at least 5 days of repeated dose (Week 1,4 or 8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of disappearance or aggravation of gastrointestinal symptom assessed by the investigators and the patient diaries</measure>
    <time_frame>From baseline to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Esophagogastroduodenoscopy(EGD) findings</measure>
    <time_frame>Pre dose and after at least 5 days of repeated dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of endoscopic presence/absence of GU, DU, AU or RE according to the EGD findings</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Gastric Ulcer (GU)</condition>
  <condition>Duodenal Ulcer (DU)</condition>
  <condition>Anastomotic Ulcer (AU)</condition>
  <condition>Non-erosive Reflux Esophagitis Disease (NERD)</condition>
  <condition>Reflux Esophagitis (RE)</condition>
  <condition>Zollinger-Ellison Syndrome</condition>
  <arm_group>
    <arm_group_label>Group 1: D961H sachet 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age: ≥1 year Weight: &lt;20 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: D961H capsule 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age: ≥1 year to 11years Weight: ≥20 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: D961H capsule 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age: ≥1 year to 11years Weight: ≥20 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: D961H capsule 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age: 12 to 14 years Weight: ≥20 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: D961H capsule 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age: 12 to 14 years Weight: ≥20 kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D961H sachet 10 mg</intervention_name>
    <arm_group_label>Group 1: D961H sachet 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D961H capsule 10mg</intervention_name>
    <arm_group_label>Group 2: D961H capsule 10mg</arm_group_label>
    <arm_group_label>Group 4: D961H capsule 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D961H capsule 20 mg</intervention_name>
    <arm_group_label>Group 3: D961H capsule 20 mg</arm_group_label>
    <arm_group_label>Group 5: D961H capsule 20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed written informed consent from the patient's guardian

          -  Patients aged ≥ 1 year to 14 years old

          -  Patients who have a diagnosis of or suspected to have GU, DU, AU, NERD, RE or
             Zollinger-Ellison syndrome.

        Exclusion Criteria:

          -  Patients less than 10 kg in weight.

          -  Use of any other investigational compounds or participations in another clinical
             trial within 4 weeks prior to the randomisation/registration.

          -  Significant clinical illness within 4 weeks prior to the registration

          -  Presence of hepatic diseases or other conditions that could interfere with evaluation
             of the study as judged by the investigators.

          -  Positive for pregnancy test by urinary or lactation for post-menarchal females.

          -  Previous total gastrectomy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Keiko Komuro</last_name>
    <phone>+81-3-6268-2740</phone>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suzaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ureshino-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>May 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric ulcer (GU)</keyword>
  <keyword>Duodenal ulcer (DU)</keyword>
  <keyword>Anastomotic ulcer (AU)</keyword>
  <keyword>Non-erosive reflux esophagitis disease (NERD)</keyword>
  <keyword>Reflux esophagitis (RE)</keyword>
  <keyword>Zollinger-Ellison syndrome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Duodenal Ulcer</mesh_term>
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Zollinger-Ellison Syndrome</mesh_term>
    <mesh_term>Gastrinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
